Related references
Note: Only part of the references are listed.Isolated adrenocorticotropic hormone deficiency possibly caused by nivolumab in a metastatic melanoma patient
Taku Fujimura et al.
JOURNAL OF DERMATOLOGY (2017)
Isolated adrenocorticotropic hormone deficiency associated with nivolumab therapy
Atsushi Narahira et al.
JOURNAL OF DERMATOLOGY (2017)
New-onset third-degree atrioventricular block because of autoimmune-induced myositis under treatment with anti-programmed cell death-1 (nivolumab) for metastatic melanoma
Juliane Behling et al.
MELANOMA RESEARCH (2017)
Nivolumab-induced hypophysitis in a patient with advanced malignant melanoma
Yudai Okano et al.
ENDOCRINE JOURNAL (2016)
Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
Julie R. Brahmer et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Share Paper
